background: In vitro maturation (IVM) of oocytes is a promising technique to reduce the costs and avert the side effects of gonadotrophin stimulation for IVF. The pregnancy rates from oocytes matured in vitro are still lower than those of in vivo stimulation cycles, indicating that optimization of IVM remains a challenge. Recently, it was demonstrated that LH exerts its action on ovulation, at least in part, through stimulation of the production of the epidermal growth factor family members amphiregulin (Areg) and epiregulin (Ereg) in pre-ovulatory follicles, and they, in turn, serve as paracrine mediators of LH. We aimed to investigate the effect of supplementation of the medium with Areg and Ereg on the maturation rate of immature oocytes.
Introduction
In vitro maturation (IVM) of oocytes is a promising technique that has the potential advantages of reducing the costs and averting the side effects of gonadotrophin stimulation for IVF. However, the efficiency of the current IVM techniques in terms of pregnancy and live birth rates do not match those reported for IVF cycles using full hormonal protocols with triggered maturation in vivo (Banwell and Thompson, 2008) . Furthermore, the quality of maturation appears to be suboptimal since embryos resulting from in vivo matured oocytes have better developmental capacity when compared with their in vitro matured counterparts. Indeed, at least one major hurdle that must be overcome before IVM becomes a mainstream procedure is the handling of immature oocytes (Piquette, 2006) .
Removing the immature cumulus -oocyte complexes (COCs) from the follicle eliminates the elements of the granulosa and theca cells and any of the influence they might have on the maturation of the oocyte. Mimicking the ovarian follicle system in vitro has been the challenge for making IVM successful. Currently, most IVM protocols supplement FSH and/or LH into the culture medium for oocyte maturation. However, the effects of FSH or LH on oocyte maturation and subsequent fertilization as well as early embryonic development are still controversial (Chian et al., 2004a) . Consequently, until the culture systems for IVM are improved, it is expected that there may be differences between in vivo and in vitro matured oocytes (Piquette, 2006) . Therefore, the strategy for increasing the efficiency of IVM is focused primarily on developing an optimal culture system for IVM (Chian et al., 2004b) . This goal could be achieved by a better understanding of the molecular events that trigger oocyte maturation, so that these events can be imitated.
The LH surge plays a central role in promoting a cascade of events in ovarian pre-ovulatory follicles that are essential for the ovulation of a fertilizable oocyte. Prior to ovulation, LH triggers a cascade of events in the ovarian follicle including resumption of meiosis of the oocyte, cumulus expansion, rupture of the follicular wall and extrusion of the cumulus -oocyte mass (reviewed in Richards et al., 2002) . While LH receptors are highly expressed on the mural granulosa cells and external theca cells, the oocyte and cumulus cells express few or no LH receptors and fail to respond when directly exposed to LH in vitro (Peng et al., 1991) . This limited number of LH receptors is especially puzzling in view of the well-established effects of LH on both the cumulus cells and the oocyte. Therefore, it was suggested that LH effects on the COC may be indirect, through the release of factors from the mural granulosa cells which propagate the LH effects in a paracrine manner toward the COC (Conti et al., 2006) .
Recently, it was demonstrated that LH stimulation of mouse preovulatory follicles induced the production and release of the epidermal growth factor (EGF) family members, amphiregulin (Areg) and epiregulin (Ereg), from the mural granulosa cells. Incubation of either pre-ovulatory follicle cultures or isolated germinal vesicle-(GV) stage COCs with Areg and Ereg recapitulated the morphological and biochemical events triggered by LH, including cumulus expansion and oocyte maturation (Park et al., 2004) . In view of these data, it was suggested that LH exerts its action, at least in part, on the COC, through stimulation of the biosynthesis of Areg and Ereg in mural granulosa cells of the pre-ovulatory follicle. These EGF-like growth factors, in turn, serve as paracrine mediators of LH.
LH stimulation of isolated human granulosa cells was found to induce a dramatic up-regulation of Areg and Ereg in both the mRNA and protein levels (Freimann et al., 2004; Ben-Ami et al., 2006a ). Likewise, it was recently found that Areg was abundantly expressed in human follicular fluid obtained from patients undergoing IVF (Inoue et al., 2009) . These data suggest that these EGF-like growth factors may mediate the LH signal in human oocyte maturation in a similar way to that found in rodents. However, to the best of our knowledge, there are no data about the effect of Areg and Ereg on human GV-stage oocytes.
The primary outcome which the present study aims to investigate is the effect of Areg and Ereg supplementation of the oocyte culture medium on the IVM rate of human GV-stage oocytes retrieved from IVF cycles. The secondary outcome is a comparison between the rates of fertilization and cleavage and indicators of embryo quality following ICSI of in vitro matured oocytes obtained following incubation with standard culture medium either with or without the addition of Areg and Ereg.
Materials and Methods

Study population
Our prospective study enrolled all women who were consecutively treated with ICSI in the IVF unit at the Assaf Harofeh Medical Center from August 2009 to March 2010 and who agreed to participate. Informed consent was obtained from all participants, and the investigation received the approval of the institutional review board. The inclusion criteria were patients having at least five mature metaphase II (MII) oocytes and, in addition, at least two GV-stage oocytes aspirated, which were divided into two groups (sibling oocytes). To minimize confounding factors, patients diagnosed with poor response (fewer than four follicles visible by sonography before oocyte retrieval), women younger than 20 and older than 40 and those with BMI ,18 kg/m 2 or .35 kg/m 2 were excluded from the study. Only one treatment cycle per patient was analyzed.
Controlled ovarian stimulation protocols and oocyte retrieval
Patients included in the study were treated by routine controlled ovarian stimulation (COS) protocols for IVF using either agonists or antagonists. In the agonist group, COS consisted of mid-luteal pituitary down-regulation, using a daily dose of GnRH agonist (nafarelin acetate, 200 mg three times a day, via intranasal spray; or triptorelin, 0.1 mg/day, via subcutaneous injection), followed by an individually adjusted daily dose of urinary or recombinant gonadotrophin injections. In the antagonist group, COS using daily injections of gonadotrophins was administered, followed by a daily dose of GnRH antagonist (0.25 mg of Cetrotide, Serono Laboratories, Geneva, Switzerland; or Orgalutran, Organon, Oss, The Netherlands) once a leading follicle of 12 mm was observed or serum estradiol levels had reached 400 pg/ml. Oocytes were retrieved 35 -38 h after administration of 10 000 IU of hCG, which was given according to similar criteria in both groups (i.e. presence of at least two leading follicles of ≥18 mm). Routine oocyte pick-up was performed using a 17G oocyte aspiration needle. Follicles were aspirated using 150 mmHg pressure.
Culture of oocytes
In spite of the fact that EGF receptor expression has been reported for oocytes (Gall et al., 2004) and that some direct effects of EGF have been observed on oocytes (Das et al., 1991; Smitz et al., 1998) , it is assumed that most of the EGF-like growth factor effects on oocyte nuclear and cytoplasmic maturation are indirect and dependent on cumulus cells (Conti et al., 2006) . According to this view, we decided to keep as many of the cumulus cells as possible in the present study. Therefore, all the oocytes obtained from the follicular aspirates were only partially removed from the surrounding cumulus oophorus using 0.1% hyaluronidase (Sigma, Rehovot, Israel) for 1 -2 min in order to facilitate the identification of GV-stage oocytes. Following this, the presence of the GV oocytes was observed, using an inverted microscope (Diaophot 300; Nikon, Japan) with a magnification of ×100, ×200 or ×400.
The oocytes identified in their GV stage were separated from the mature oocytes. Sibling oocytes of similar size, cumulus cell status and appearance were randomly allocated to culture media (G-1Ô v5, Vitrolife, CT, USA) supplemented with human serum albumin either with or without supplementation with recombinant human Areg (75 ng/ml, R&D Systems, MN, USA) and Ereg (75 ng/ml, R&D Systems) for 24 h. The combination of Areg and Ereg as well as their mentioned concentrations are based on earlier studies. Physiologically, Areg and Ereg accumulate at the same time and therefore have additive or synergistic effects on oocyte maturation (Conti et al., 2006) . In Areg null mice, oocyte maturation occurred with a delay (Hsieh et al., 2007) , a finding consistent with the idea that Areg and Ereg synergize to accelerate maturation. Therefore, we decided to add Areg and Ereg in combination to the culture medium.
IVM experiments in rodents demonstrated similar dose-response effects of Areg and Ereg on the maturation rate of GV-stage oocytes (Park et al., 2004) . Therefore, we decided to add similar concentrations of Areg and Ereg to the culture medium. The concentration of Areg in the follicular fluid of women who underwent IVF treatment following EGF-like growth factors improve IVM of human GV oocytes hCG administration was found to be 108.4 + 6.3 ng/ml (Inoue et al., 2009) . Since this concentration was measured following administration of 10 000 IU of hCG, we decided to use lower doses of Areg and Ereg in the present study. Neither culture media was supplemented with gonadotrophins.
The oocytes were observed under an inverted microscope (Diaophot 300) after 24 h incubation. Oocyte maturation was determined by GV breakdown (GVBD)/metaphase I or MII stages. Only oocytes reaching MII were used for ICSI.
Previous studies have demonstrated that in IVM cycles, the oocytes which have matured in vitro on Day 1 have significantly higher rates of fertilization and cleavage than those matured later on (Son et al., 2005 (Son et al., , 2008 . Likewise, previous studies, investigating the clinical outcome of immature oocytes retrieved from stimulated ICSI cycles, have demonstrated that early matured oocytes yield significantly higher fertilization and developmental potential than their later matured counterparts (Balakier et al., 2004; Shu et al., 2007) . Based on these data, we decided to compare the maturation rate following 24 h of incubation and not thereafter. Hence, oocytes that did not reach MII following 24 h of incubation in either group were discarded.
ICSI procedure
The matured oocytes were injected with frozen -thawed donor sperm. The procedure was carried out according to the methodology described by Van Steirteghem et al. (1993) . Culture of the injected oocytes took place in 25 ml medium droplets under oil for embryo culture (Irvine Scientific, CA, USA). Oocytes were observed for fertilization 16 -18 h after micromanipulation. Normal fertilization was defined as the presence of two extruded polar bodies and two pronuclei. Cleavage was assessed 24 and 48 h later and the embryos were classified according to their morphological appearance: Grade I, symmetrical blastomeres with no enucleated fragments; Grade II, asymmetrical blastomeres with or without ,20% of the volume filled with enucleated fragments; Grade III, blastomeres with 20 -50% of the volume covered with fragments; and Grade IV, extremely asymmetrical blastomeres and .50% of the volume filled with enucleated fragments. Following the attainment of Day 2 embryos, they were all discarded.
Statistical analysis
Differences in oocyte maturational stages, as well as fertilization and cleavage rates, were calculated by x 2 test and Fischer's exact test, as appropriate. Differences in means between two variables were calculated using Student's t-test or the analysis of variance test, as appropriate. P , 0.05 was considered statistically significant. Calculations were performed using SPSS software (version 11, Cary, IL, USA).
Results
A total of 30 patients were included, 26 treated by agonists and 4 by antagonists. The mean age of the study group (+ SD) was 30.2 + 4.3 years (range: 20-40 years) and the mean BMI was 25.3 + 5.2 kg/m 2 .
The major indications for assisted reproduction techniques included male factor infertility (57%), unexplained infertility (20%), tubal factor infertility (13%) and polycystic ovary syndrome (10%). The mean number of previous IVF cycles in the study group was 2.9 + 2.2. The mean peak serum estradiol on the hCG day was 2730 + 1246 pg/ml. The mean number of retrieved oocytes was 16.6 + 6. The mean number of cleaved embryos was 7.8 + 4.5 and the number of embryos transferred per patient was 2.1 + 0.8 with a mean morphology score of 1.4 + 0.4.
A total of 105 human GV-stage oocytes were included in the study, of which 52 were incubated in the standard culture medium and 53 sibling oocytes were cultured in the same medium supplemented with Areg and Ereg. The mean number of GV-stage oocytes per patient was 3.5 + 1.8 (range 2 -8).
The maturation stage of the GV-stage oocytes following 24 h of incubation either in the standard medium or in the same medium supplemented with Areg and Ereg is presented in Table I . A significantly higher rate of GV-stage oocytes cultured in the medium enriched with Areg and Ereg reached MII stage at 24 h compared with those cultured in the standard medium (75.5 versus 36.5%, respectively, P , 0.001). Significantly more oocytes in the standard medium were found to be degenerative when compared with those cultured in the medium supplemented with Areg and Ereg (P ¼ 0.01).
The oocytes reaching MII following 24 h of incubation in both the study and the control groups underwent ICSI, and their fertilization outcome are presented in Table II . There were no statistically significant differences between the rates of both normal (2PN) and abnormal (1PN, 3PN and 4PN ) fertilizations between oocytes matured in the standard medium when compared with those matured in the medium supplemented with Areg and Ereg. The cleavage outcome of the normally fertilized oocytes (2PN) retrieved from the study and the control groups are presented in Table III . There were no significant differences in the rates of Day 2 and Day 3 embryos, the mean numbers of blastomeres or the morphology scores between the two subgroups. Taken together, out of the total cohort of GV-stage oocytes, a significantly higher number of MII oocytes fertilized normally (reaching 2PN) following ICSI in the Areg-and Ereg-supplemented medium than those cultured in the standard medium [28 out of 53 (52.8%) versus 14 out of 52 (26.9%), respectively, P , 0.01], all of which cleaved in both groups. There were 24 out of 53 (45.2%) Day 3 embryos with 6-8 blastomers in the study group compared with 12 of 52 (23%) in the controls, P , 0.05).
Discussion
Ovulation induction techniques aim to maximize oocyte maturation in vivo; however, 5-15% of aspirated oocytes remain at the GV stage at the time of oocyte retrieval (Janssenswillen et al., 1995; Farhi et al., 1997) . Why these oocytes fail to complete nuclear maturation remains speculative; the follicles may be resistant or less responsive to hormonal stimulation (Farhi et al., 1997) or they simply may be at an earlier developmental stage (Kim et al., 2000) . The latter is the most likely scenario as, with further culture, a cohort will complete nuclear maturation, fertilize and initiate embryonic development (Janssenswillen et al., 1995; Farhi et al., 1997; Goud et al., 1998; Haberle et al., 1999; Kim et al., 2000) . Although several case reports have described successful pregnancies and even live births achieved using such in vitro matured oocytes (Nagy et al., 1996; Edirisinghe et al., 1997; Tucker et al., 1998) , it is well accepted that in IVF cycles oocytes that remain immature at the time of oocyte collection are not suitable for ICSI. These immature oocytes are generally used for research such as investigations of the effects of the culture media on the completion of oocyte maturation (Roberts et al., 2002) . In light of the lack of knowledge about the possible effects of Areg and Ereg on human GV-stage oocytes, we decided to examine the effect of these EGF-like growth factors on immature oocytes retrieved from IVF cycles.
In the present study, we found that supplementation of the maturation medium with Areg and Ereg significantly improved the maturation rate of human GV oocytes in vitro, yielding larger number of human embryos. To the best of our knowledge, this is the first study that addresses this issue. Importantly, we found a significantly higher rate of MII oocytes following 24 h of incubation in the supplemented media. This time point could be important clinically, as it was found that in IVM cycles human GV-stage oocytes matured on Day 1 were of significantly higher quality than those matured later on (Son et al., 2005) .
The basal IVM rate of GV-stage oocytes retrieved from stimulated cycles differs widely between studies. Differing reports of IVM rates are probably due to several factors, including media composition, hormone/growth factor supplementation, the source of oocytes (unstimulated versus stimulated cycles) and whether or not cumulus cells are retained with the oocyte (Combelles et al., 2002) . In the present study, the IVM rate seen over a 24 h period in the control group (36.5%) is comparable with previous studies exploring the IVM rate of GV-stage oocytes collected from stimulated cycles (Cha and Chian, 1998; Kim et al., 2000) . Interestingly, this IVM rate is also comparable with that achieved in IVM cycles (Son et al., 2008) , indicating that the beneficial effect of addition of gonadotrophins to the maturation media of IVM cycles is questionable (Chian et al., 2004a) .
Retrieval of immature human oocytes followed by IVM and fertilization has resulted in viable offspring, with a considerable degree of success (Son et al., 2008) . However, the pregnancy rates with IVM are significantly lower when compared with in vivo matured oocytes obtained during gonadotrophin-stimulated cycles (Piquette, 2006) . This can mainly be attributed to the relatively lower number of oocytes that mature, fertilize and finally develop successfully into embryos that implant. Nevertheless, further investigations are needed since IVM offers a number of advantages, such as prevention of ovarian hyperstimulation syndrome, reduced costs and relief from anxiety over the potential long-term side effects of ovarian stimulation drugs. It also provides the opportunity to transfer the embryos during a natural cycle or during cycles that have minimal drug supplementation (Chian et al., 2004a) .
Of all ovarian growth factors, it seems that EGF-like factors have received considerable attention in recent years, reflecting the discovery of their crucial role in reproduction. Initially, it was found more than two decades ago that EGF has the potential to induce expansion of the cumulus cells surrounding the oocyte in rats (Dekel and Sherizly, 1985) . Thereafter, EGF was found to play a positive role in various mammalian in vitro systems of oocyte maturation (reviewed in Ben-Ami et al., 2006b) . EGF was also shown to induce GVBD and nuclear maturation when added to human GV-stage oocytes (Goud et al., 1998) . Interestingly, maintenance of the cumulus during culture improved the nuclear and cytoplasmic maturation of human oocytes, suggesting an indirect effect of EGF on the oocyte. It was, therefore, puzzling that according to a DNA microarray, there was no detectable expression of EGF in human granulosa cells obtained from an IVF program. Taken together, in spite of its competence to induce IVM of GV-stage oocytes of various species, EGF was not considered as an integral part of gonadotrophin-induced ovulation cascade (Ben-Ami et al., 2006b) More recent studies found that LH stimulation of mural granulosa cells from pre-ovulatory follicles induces a dramatic up-regulation of the EGF-like growth factors Areg, Ereg and betacellulin. Incubation of GV-stage mouse follicles with these growth factors recapitulated the morphological and biochemical events triggered by LH, including cumulus expansion and oocyte maturation (Park et al., 2004) . It should be noted, however, that as opposed to Areg and Ereg, no change in gene transcripts for betacellulin was demonstrated by us in human granulosa cell cultures following LH stimulation using a DNA microarray technique (Ben-Ami et al., 2006b) . Since betacellulin does not take part in the human ovulatory processes, it was not added to the culture medium.
It was suggested that LH activation of mural granulosa cells induces the expression of Areg and Ereg, which activate the EGF receptors in the COC, thus triggering oocyte maturation, acquisition of developmental competence as well as cumulus expansion. Better understanding of the possible involvement of EGF-like growth factors in follicle growth and oocyte maturation should prompt, according to Conti et al. (2006) , a reassessment of growth media formulation for IVM, in view of the well-established beneficial effects of EGF on oocyte acquisition of developmental competence and overall oocyte quality. Indeed, EGF-like growth factors have been found to play a positive role in various mammalian in vitro systems of oocyte maturation (reviewed in Hsieh et al., 2009) .
We are aware of the potential limitations of the present study, namely the relatively small sample size of the cohort GV-stage oocytes, the usage of a medium designed for embryo culture instead of the commercially available IVM medium, as well as the time limitation of oocyte culturing for 24 h. Indeed, future studies are needed to address the potential effects of Areg and Ereg regarding the regulation of meiotic maturation and acquisition of oocyte developmental competence in the human. Ideally these should include immature oocytes retrieved from IVM cycles, the use of commercially available IVM medium, and detailed time and dose-response effects of Areg, Ereg and their combination, as well as any potential synergistic effect of gonadotrophins and the EGF-like growth factors, Areg and Ereg, in the culture medium.
In conclusion, this work has shown, for the first time, that enrichment of the maturation medium with the EGF-like growth factors Areg and Ereg significantly improved the maturation rate of human GV oocytes in vitro. This significantly higher rate of in vitro matured oocytes enabled the production of a larger number of human embryos. The fact that Areg and Ereg significantly affect the IVFderived GV-stage human oocyte IVM rate suggests that their supplementation of the culture medium of IVM-derived GV-stage human oocyte might improve the rates of IVM, embryo production and, possibly, pregnancy. These findings could, therefore, serve as the basis for future research on the effect of Areg and Ereg supplementation of the maturation media of GV-stage oocytes retrieved in IVM cycles.
